Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0006304,
umls-concept:C0021747,
umls-concept:C0039194,
umls-concept:C0042210,
umls-concept:C0086418,
umls-concept:C0237401,
umls-concept:C0560175,
umls-concept:C1415900,
umls-concept:C1524063,
umls-concept:C1527148,
umls-concept:C1552644,
umls-concept:C1706209,
umls-concept:C1823153,
umls-concept:C2349976
|
pubmed:issue |
4
|
pubmed:dateCreated |
1992-7-16
|
pubmed:abstractText |
Brucella abortus has been characterized as a T-independent type 1 antigen/carrier in human and murine antibody responses. In this report it is shown that BA can activate human CD3+ T cells to secrete interferon-gamma (IFN gamma). Unlike mitogens, such as phytohemagglutinin, this stimulation was associated with minimal T-cell proliferation or upregulation of interleukin-2 (IL-2) receptor. Monocytes inhibited BA-mediated IFN gamma secretion since their removal resulted in increased responses, whereas adding monocytes back to cultures caused inhibition. BA elicited IFN gamma from CD4+ and CD8+ T cells, although CD4+ T cells secrete significantly more (p less than 0.05) IFN gamma than CD8+ T cells. The ability of BA to elicit IFN gamma from human T cells was inhibited in the presence of anti-Tac, suggesting that BA also induces IL-2 secretion and that IL-2 is involved in BA-mediated IFN gamma secretion. Detectable IL-2 secretion was induced by BA in the presence of anti-Tac. Exogenous IL-2 acted synergistically with BA to enhance IFN gamma secretion, suggesting that the amount of IL-2 released by BA alone was insufficient for optimal IFN gamma release. Furthermore, addition of IL-2 to T cells from individuals with poor or absent responses to BA, including individuals infected with HIV-1, restored their ability to secrete IFN gamma in response to BA. These data indicate that BA is capable not only of activating human B cells but can also induce T cells, probably of the TH1 phenotype, to secrete IFN gamma.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0889-2229
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
8
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
479-86
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:1350916-Antigens, CD8,
pubmed-meshheading:1350916-Brucella abortus,
pubmed-meshheading:1350916-CD4-Positive T-Lymphocytes,
pubmed-meshheading:1350916-Cells, Cultured,
pubmed-meshheading:1350916-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:1350916-HIV Infections,
pubmed-meshheading:1350916-Humans,
pubmed-meshheading:1350916-Interferon-gamma,
pubmed-meshheading:1350916-Monocytes,
pubmed-meshheading:1350916-Receptors, Interleukin-2,
pubmed-meshheading:1350916-T-Lymphocytes,
pubmed-meshheading:1350916-Viral Vaccines
|
pubmed:year |
1992
|
pubmed:articleTitle |
Brucella abortus stimulates human T cells from uninfected and HIV-infected individuals to secrete IFN gamma: implications for use of Brucella abortus as a carrier in development of human vaccines.
|
pubmed:affiliation |
Division of Hematology, U.S. Food and Drug Administration, Bethesda, MD 20892.
|
pubmed:publicationType |
Journal Article
|